Johannes Lutz

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

M. Fotin‐Mleczek, Patrick Baumhof, M. Hope, 2017, npj Vaccines.

RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines.

T. Schlake, A. Kowalczyk, R. Heidenreich, 2017, Methods in molecular biology.

Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity

M. Meister, A. Kowalczyk, K. Fiedler, 2022, Cancer Immunology, Immunotherapy.

A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

S. Voss, M. Fotin‐Mleczek, Patrick Baumhof, 2015, International journal of cancer.

mRNA Cancer Vaccines.

K. Fiedler, R. Heidenreich, S. Lazzaro, 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.